Survanta Suspension

Survanta Suspension
Survanta Suspension
Price And Quantity
  • Box/Boxes
  • 500
  • Box/Boxes
  • 2-5 USD ($)
    Product Specifications
    • Drug Solutions
    • Liquid
    • Dry Place
    Product Description

    Survanta Suspension

    Product Specifications

    Drug Type

    Generic Drugs

    Physical Form


    Dosage Guidelines

    Consult your Doctor

    Suitable For

    Suitable For All

    Product Description

    We have gained immense appreciation from clients for exporting an excellent stock of Survanta 8ml (Beractant Intratracheal). The medication is intended for intratracheal use only. This Survanta 8ml (Beractant Intratracheal) is indicated for the treatment of respiratory distress syndrome (RDS), also known as hyaline membrane disease, in newborn premature infants. We make sure to procure this medicine from the trusted and renowned vendors of the market.

    Therapeutic indications

    Survanta is indicated for treatment of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in new born premature infants with a birth weight of 700g or greater and who are intubated and are receiving mechanical ventilation.Survanta is also indicated for the prophylactic treatment of premature infants <32 weeks gestational age at risk of developing RDS.

    Key points:

    • It is a sterile and non-pyrogenic pulmonary surfactant
    • The medication is a natural bovine lung extract
    • It contains phospholipids, neutral lipids, fatty acids and surfactant-associated protein



    • Brand: Survanta Susp
    • Contain: Beractant Intratracheal
    • Strength :4ml / 8ml
    • Packing: Susp


    Pharmacodynamic properties

    Pharmacotherapeutic group: Lung Surfactant

    • The mode of action of Survanta is biophysical rather than biochemical, i.e. it reduces surface tension and concomitantly increases lung compliance.
    • Intratracheally administered Survanta distributes rapidly to the alveolar surfaces and stabilises the alveoli against collapse during respiration thereby increasing alveolar ventilation.
    • In clinical studies of premature infants with Respiratory Distress Syndrome (RDS), a significant improvement in oxygenation was demonstrated after treatment with a single dose of Survanta.
    • These infants showed a decreased need for supplemental oxygen and an increase in the arterial/alveolar oxygen ratio (a/Ap02). Significantly decreased need for respiratory support, as indicated by a lower mean airway pressure, was also observed. In most cases these effects were maintained for at least 72 hours after the administration of the single dose of Survanta.


    Pharmacokinetic properties

    In preclinical studies using radiolabelled phosphatidylcholine, the clearance rate of Survanta in the lung of three day old rabbits has been shown to be similar to that of natural calf and sheep surfactants (approximately 13% within 24 hours). In addition some re-uptake and secretion of Survanta was shown, implying its entry into a metabolically active surfactant pool.

    Since an exogenous preparation of Survanta is delivered directly to the lung, classical clinical pharmocokinetic parameters (blood levels, plasma half-life etc.) have not been studied.

    Preclinical safety data

    There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

    Special precautions for disposal and another handling

    Each vial of Survanta is for single use only. Used vials with the residual drug should be discarded.Survanta should be inspected visually for discoloration prior to administration. The colour of Survanta is off-white to light brown. Some settling may occur during storage. If this occurs, gently invert the vial several times (DO NOT SHAKE) to redisperse.Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

    Trade Information
    • Mundra Port
    • Paypal, Western Union, Telegraphic Transfer (T/T), Letter of Credit at Sight (Sight L/C), Letter of Credit (L/C), Cash in Advance (CID), Cash Advance (CA)
    • 10000 Per Month
    • 30 Days
    • Yes
    • Sample costs shipping and taxes has to be paid by the buyer
    • As Per Buyer Requirements
    • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia
    • All India
    • ISO, WHO, GMP, FDA
      Related Products
      Tenecteplase Injection

      Send Inquiry
      Mometasone Furoate Nasal Spray

      Send Inquiry
      Natalizumab Injection

      Send Inquiry
      Benzoyl Peroxide Cream

      Send Inquiry
      Leuprolide acetate Injection

      Send Inquiry
      Imatinib Tablet

      Send Inquiry
      right arrow
      left arrow
      Contact Us

      TPM, Yogi Chowk,, Surat, Gujarat, 395010, India
      Phone :+918037400926